Published in Clin Exp Immunol on May 01, 1987
Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope. J Virol (1997) 1.27
Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12. J Virol (2001) 0.90
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet (1972) 5.17
Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol (1978) 5.02
The regulatory role of macrophages in antigenic stimulation. Part Two: symbiotic relationship between lymphocytes and macrophages. Adv Immunol (1981) 4.72
Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med (1986) 4.51
Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet (1983) 4.01
Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology (1982) 2.74
Selective detection of IgM-antibody against core antigen of the hepatitis B virus by a modified enzyme immune assay. J Med Virol (1979) 2.68
Mechanisms by which activated macrophages inhibit lymphocyte responses. Immunol Rev (1978) 2.24
Hepatitis B virus core antigen: synthesis in Escherichia coli and application in diagnosis. Proc Natl Acad Sci U S A (1982) 2.19
The conversion of hepatitis B core antigen synthesized in E coli into e antigen. J Med Virol (1981) 2.11
Viral hepatitis, type B. Studies on natural history and prevention re-examined. N Engl J Med (1979) 2.03
T and B lymphocytes in acute and chronic hepatitis. Clin Immunol Immunopathol (1974) 1.98
High-frequency transfection and cytopathology of the hepatitis B virus core antigen gene in human cells. Science (1983) 1.67
The relationship between human helper and suppressor factors to a streptococcal protein antigen. J Immunol (1982) 1.43
Recognition of viral antigens by human influenza A virus-specific T lymphocyte clones. J Immunol (1985) 1.40
Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology (1984) 1.38
Protection against hepatitis B virus infection by immunization with hepatitis B core antigen. Gastroenterology (1985) 1.32
Activation and immunoregulation of antigen-specific human b lymphocyte responses: multifaceted role of the monocyte. J Immunol (1982) 1.29
Core antigen-specific immunoglobulin G bound to the liver cell membrane in chronic hepatitis B. Gastroenterology (1982) 1.24
The human autologous mixed lymphocyte reaction. I. Suppression by macrophages and T cells. J Immunol (1981) 1.21
Detection of cellular and humoral immunity to hepatitis B surface antigen (HBsAg) in asymptomatic HBsAg carriers. Clin Exp Immunol (1985) 1.09
Importance of HLA-D antigens for the cooperation between human monocytes and T lymphocytes. Eur J Immunol (1978) 1.06
Antibody production and DNA synthesis of human lymphocyte subpopulations induced by PPD tuberculin. Clin Exp Immunol (1979) 1.03
In vitro response to HBsAg of peripheral blood lymphocytes from recipients of hepatitis B vaccine. Hepatology (1984) 1.00
Regulatory functions of T- and accessory-cells for hepatitis B surface antigen induced specific antibody production and proliferation of human peripheral blood lymphocytes, in vitro. J Clin Lab Immunol (1985) 0.96
Lymphocyte transformation and the number of antigen-responsive cells in humans. J Immunol (1981) 0.96
Passive and active immunoprophylaxis of hepatitis B. Gastroenterology (1984) 0.95
Purification of hepatitis B surface antigen by affinity chromatography. Vox Sang (1978) 0.90
A two-step procedure for the purificaton of hepatitis B surface antigen (HBsAg). Vox Sang (1981) 0.84
Antigen presentation and regulatory functions of human monocytes in the in vitro response of lymphocytes against purified protein derivative of tuberculin (PPD). Eur J Immunol (1981) 0.80
Human serum albumin and the enigma of chronic hepatitis type B. Scand J Immunol (1986) 0.77
Prevention of hepatitis B by recombinant DNA hepatitis B vaccine. Neth J Med (1986) 0.76
A solid-phase radioimmunoassay for detection of IgM antibodies to hepatitis A virus. J Infect Dis (1979) 3.15
Detection of IgM antibodies to cytomegalovirus (CMV) using an enzyme-labelled antigen (ELA). J Gen Virol (1980) 2.13
Nucleotide sequence of wild-type hepatitis A virus GBM in comparison with two cell culture-adapted variants. J Virol (1994) 1.80
Persistent infection of human fibroblasts by hepatitis A virus. J Gen Virol (1984) 1.72
Proteases of Pseudomonas aeruginosa in patients with cystic fibrosis. J Infect Dis (1983) 1.56
Detection of hepatitis A virus in sewage sludge by antigen capture polymerase chain reaction. Appl Environ Microbiol (1993) 1.42
Seroepidemiological investigation of patients and family contacts in an epidemic of hepatitis A. J Med Virol (1977) 1.39
Hepatitis A-virus in cell culture: I. propagation of different hepatitis A-virus isolates in a fetal rhesus monkey kidney cell line (Frhk-4). Med Microbiol Immunol (1980) 1.39
Liver-derived cytotoxic T cells in hepatitis A virus infection. J Infect Dis (1989) 1.29
Cell-mediated cytotoxicity in hepatitis A virus infection. Hepatology (1987) 1.23
Hepatitis A virus in cell culture. II. Growth characteristics of hepatitis A virus in Frhk-4/R cells. Med Microbiol Immunol (1981) 1.21
Acid stability of hepatitis A virus. J Gen Virol (1989) 1.18
Detection of cellular and humoral immunity to hepatitis B surface antigen (HBsAg) in asymptomatic HBsAg carriers. Clin Exp Immunol (1985) 1.09
Mutational events in consecutive passages of hepatitis A virus strain GBM during cell culture adaptation. Virology (1994) 1.02
Antigenicity of hepatitis A virus after ultra-violet inactivation. Vaccine (1995) 1.02
Hepatitis A virus in cell culture. III. Propagation of hepatitis A virus in human embryo kidney cells and human embryo fibroblast strains. Med Microbiol Immunol (1981) 0.99
Human gamma interferon production by cytotoxic T lymphocytes sensitized during hepatitis A virus infection. J Virol (1988) 0.98
Comparison of ozone inactivation, in flowing water, of hepatitis A virus, poliovirus 1, and indicator organisms. Appl Environ Microbiol (1989) 0.95
Application of a solid-phase radioimmunoassay and immune electron microscopy for hepatitis A in diagnosis and research. Med Microbiol Immunol (1978) 0.93
Recombination of influenza A strains with fowl plague virus can change pneumotropism for mice to a generalized infection with involvement of the central nervous system. Virology (1980) 0.91
Hepatitis A virus infection and the interferon system. J Infect Dis (1985) 0.91
Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature (1981) 0.91
Properties of a hepatitis A virus candidate vaccine strain. J Gen Virol (1987) 0.88
Hepatitis A-virus particles in stools of patients from a natural hepatitis outbreak in Germany. Med Microbiol Immunol (1977) 0.88
Levels of neutralizing and binding antibodies to hepatitis-A virus after onset of icterus: a comparison. J Infect Dis (1984) 0.87
Genetic relatedness of Cuban HAV wild-type isolates. J Med Virol (2001) 0.86
Identification of GBV-C hepatitis G RNA in chronic hepatitis C patients. J Med Virol (1996) 0.85
Lack of complement-dependent cytolytic antibodies in hepatitis A virus infection. J Med Virol (1986) 0.84
Immunogenicity of a hepatitis A virus vaccine. J Med Virol (1987) 0.84
Detection of hepatitis A virus RNA in commercially available factor VIII preparation. Lancet (1992) 0.84
Transmission of hepatitis A virus infection despite vaccination. N Engl J Med (2000) 0.84
New epidemiological patterns of hepatitis A and B infections in Germany. Zentralbl Hyg Umweltmed (1995) 0.83
Sequence variability of hepatitis A virus and factor VIII associated hepatitis A infections in hemophilia patients in Europe. An update. Vox Sang (1994) 0.83
Influence of the 5' noncoding region of hepatitis A virus strain GBM on its growth in different cell lines. J Gen Virol (1997) 0.81
Cellular immune responses to hepatitis B virus antigens in man. Liver (1991) 0.81
Influenza virus: association of mouse-lung virulence with plaque formation in mouse kidney cells. Intervirology (1976) 0.81
Specific detection of minus strand hepatitis A virus RNA by Tail-PCR following reverse transcription. Nucleic Acids Res (1994) 0.81
Inhibition of in vitro hematopoiesis by hepatitis A virus. Exp Hematol (1987) 0.81
A comparison of enzyme-immunoassay and radioimmunoassay for detection of hepatitis A virus and antibodies against hepatitis A virus. J Biol Stand (1984) 0.80
Antitumor activity of the pineal gland: effect of unidentified substances versus the effect of melatonin. Oncology (1992) 0.80
Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients. Eur J Med Res (2011) 0.79
Myelopoiesis in vitro is suppressed by hepatitis A virus. Ann Hematol (1992) 0.79
HBsAg-induced interferon-gamma secretion in T cells from asymptomatic HBsAg carriers and HB-immune donors in vitro. Immunology (1990) 0.79
Immunogenicity and efficacy of a killed hepatitis A vaccine in day care center children. J Med Virol (1996) 0.79
Detection of hepatitis A virus in a factor VIII preparation by antigen capture/PCR. Vox Sang (1994) 0.78
Quantitative monitoring of serum hepatitis B virus DNA and blood lymphocyte subsets during combined prednisolone and interferon-alpha therapy in patients with chronic hepatitis B. J Viral Hepat (1999) 0.78
Immune response to hepatitis A virus capsid proteins after infection. J Clin Microbiol (1996) 0.78
Acute viral hepatitis, types A, B and non-A, non-B: a prospective study of the epidemiological, laboratory and prognostic aspects in 280 consecutive cases. Scand J Infect Dis (1981) 0.78
Molecular epidemiology of an outbreak of hepatitis A in Italy. J Med Virol (1995) 0.77
Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C. Biologicals (1996) 0.77
Functional significance of neuraminidase in the replication cycle of influenza viruses. Zentralbl Bakteriol Orig A (1975) 0.76
Influenza virus: appearance of high mouse-neurovirulent recombinants. Intervirology (1979) 0.76
Preliminary characterization of a fast-growing strain of human hepatitis A virus. Microbiologica (1986) 0.75
Hepatitis G virus infection. Lancet (1997) 0.75
Hepatitis A-virus in cell culture. V. Neutralizing antibodies against hepatitis A-virus. Med Microbiol Immunol (1984) 0.75
Hepatitis C virus, rheumatoid factors, and disease progression. Lancet (1998) 0.75
[Methods for the detection of enteroviruses and coliphages in water of different sources]. Schriftenr Ver Wasser Boden Lufthyg (1988) 0.75
Partial purification of (a) low molecular weight ovine pineal compound(s) with an inhibiting effect on the growth of human melanoma cells in vitro. J Neural Transm (1988) 0.75
HBcAg induced T-cell independent anti-HBc production in chronic HBsAg carriers. Arch Virol Suppl (1992) 0.75
Isolation of single stranded DNA from purified hepatitis A-virus. Z Naturforsch C (1978) 0.75
Anti-hepatitis E virus markers in hemodialysis patients. Nephron (1996) 0.75
Significance of pre-S2 peptide of hepatitis B virus: should it be in the vaccine? Prog Med Virol (1988) 0.75
Quantitative determination of immune response against hepatitis A virus capsids after natural infection. Vaccine (1996) 0.75
[Epidemiology and clinical aspects of non-A, non-B hepatitis (author's transl)]. Dtsch Med Wochenschr (1980) 0.75
[A trial of a hepatitis A cultured inactivated vaccine on rhesus macaques]. Zh Mikrobiol Epidemiol Immunobiol (1995) 0.75
IgM anti-preS2 monitoring during combined corticosteroid/interferon-alpha 2b therapy in chronic hepatitis B. Liver (1991) 0.75
Transmission of hepatitis E virus by transfusion? Lancet (1993) 0.75
Hepatitis E virus in haemodialysis. Vox Sang (1997) 0.75
Acute viral hepatitis A, B and non-A, non-B in Stockholm in the 1950s and 1970s: a comparison. Infection (1981) 0.75
Is the use of the term 'posttransfusion hepatitis type B' in its conventional sense still justifiable? Vox Sang (1983) 0.75
Partial purification of a polypeptide extract derived from ovine pineal that suppresses the growth of human melanoma cells in vitro. J Pineal Res (1989) 0.75
[Isolation of infectious hepatitis A viruses from clearing sludge]. Z Gesamte Hyg (1988) 0.75
Adsorption properties of different hepatitis B virus related antigens (HBsAg, HBcAg, HBeAg) on octanohydrazide-Sepharose 4B. J Virol Methods (1984) 0.75
Limitations of commercial test for antibody to hepatitis A virus. Lancet (1979) 0.75
Hepatitis A. Baillieres Clin Gastroenterol (1990) 0.75
Hepatitis A-virus in cell culture. IV. Comparison of cell-culture-produced HAV with stool-derived HAV in diagnostic test systems. Med Microbiol Immunol (1984) 0.75
[Results from the hepatitis A-virus diagnostic of the hygiene-institut in Tübingen]. Zentralbl Bakteriol Mikrobiol Hyg A (1982) 0.75
[Epidemiology, clinical data and immune response of an epidemic of hepatitis A (author's transl)]. Dtsch Med Wochenschr (1978) 0.75
Hepatitis A virus and polymerase chain reaction amplification: methodology and results. Blood Coagul Fibrinolysis (1995) 0.75
Growth-inhibiting effect of crude pineal extracts on human melanoma cells in vitro is different from that of known synthetic pineal substances. J Neural Transm (1987) 0.75